Page 6 - உலகளாவிய வெளிப்புறம் தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Allison Transmission Awarded $3 6 Million Engineering Contract to Maintain Superior Performance of the Abrams Powertrain

Press release content from Business Wire. The AP news staff was not involved in its creation. Allison Transmission Awarded $3.6 Million Engineering Contract to Maintain Superior Performance of the Abrams Powertrain February 3, 2021 GMT INDIANAPOLIS (BUSINESS WIRE) Feb 3, 2021 The U.S. Army selected Allison Transmission, the largest global manufacturer of medium- and heavy-duty fully automatic transmissions for commercial and military vehicles, to undertake an engineering program that builds upon previous analysis and evaluates the X1100-3B1 transmission and final drive changes necessary to expand the Abrams’ performance edge in speed, cruising range and durability. The Abrams tank, introduced in the early 1980s, has been the subject of continuous capability improvements throughout its service life. This effort represents a deliberate plan by U.S. Army program managers and engineers to maintain the superior performance necessary to succeed in combat.

United statesClaire gregoryDana pittardArmy program officeUs armyGlobal external communicationsAllison transmissionVice presidentDefense programsProgram officeGlobal externalBusiness wireஒன்றுபட்டது மாநிலங்களில்கிளாரி கிரெகொரிடானா பித்தார்த்இராணுவம் ப்ரோக்ர்யாம் அலுவலகம்

LEO Pharma initiates head-to-head study to evaluate brodalumab vs guselkumab in adult patients with moderate-to-severe psoriasis who have inadequate response to ustekinumab

Posted on 7466 LEO Pharma A/S – a global leader in medical dermatology – announced today that the first patient has been screened in the first head-to-head clinical trial to evaluate brodalumab (marketed in the European Union as Kyntheum ®) compared with guselkumab (marketed globally as Tremfya ®) in adult patients with moderate-to-severe plaque psoriasis who have an inadequate response to ustekinumab (marketed globally as Stelara ®) treatment. Per Sproegel (Photo: Business Wire) The COBRA (COmparing BRodalumab And guselkumab in ustekinumab inadequate responders) clinical trial is a randomized, double-blind, parallel-group, multinational study. The primary study endpoint is the proportion of patients who achieve PASI 100 (100% skin clearance) at week 16. The study further includes several secondary and exploratory endpoints, including the key secondary endpoint of time to PASI 100 response while on treatment

Kristian reichHenrik kyndlevEuropean union as kyntheumGlobal research developmentGlobal external communicationsUniversity medical center hamburg eppendorfEuropean unionBusiness wireTranslational researchInflammatory skin diseaseUniversity medical center hamburgPer sproegelVice presidentMedical sciencesGlobal researchDrugs dermatol

BioNTech SE: BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine

BioNTech SE: BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine A local Phase 2 clinical trial of mRNA COVID-19 vaccine candidate BNT162b2 is on-going in Jiangsu, China MAINZ, GERMANY, and SHANGHAI, CHINA, December 16, 2020( Fosun Pharma or Group ; Stock Code: 600196.SH, 02196.HK) today announced an agreement to supply Mainland China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19 in 2021, subject to regulatory approval. Initial supply will be delivered from BioNTech s production facilities in Germany. We would like to thank the Chinese government and National Medical Products Administration for their commitment and trust in our vaccine development efforts to help address this global pandemic threat, said

Barney liuWu yifangUgur sahinFosun pharmaFosun pharma or groupMechanism of the state councilNational health commissionShanghai fosun pharmaceutical group co ltdInnovation for good healthBayer animal healthNational medical products administrationRoche groupGlobal external communicationsMinistry of scienceStock codeMainland china

BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine

BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine
marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.

Barney liuWu yifangUgur sahinFosun pharmaFosun pharma or groupMechanism of the state councilNational health commissionShanghai fosun pharmaceutical group co ltdInnovation for good healthBayer animal healthNational medical products administrationRoche groupGlobal external communicationsMinistry of scienceFosun pharmaceuticalStock code

BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine – IT Business Net

BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.